Loading…
Loading…
T-cell lymphoma is a heterogeneous group of lymphoid cancers that requires expert pathology and subtype-specific treatment.
Quick Answer
T-cell lymphoma is a heterogeneous group of lymphoid cancers that requires expert pathology and subtype-specific treatment. Dr. Sachita Baniya (NMC 20158, 8+ years of clinical experience in haematology and haemato-oncology) evaluates t-cell lymphoma at Kathmandu Neurology Clinic & Cognitive Center, 117 Lal Durbar Marg, Kathmandu, Bagmati Province 44600, Nepal — evidence-based, medically reviewed.
T-cell lymphomas include nodal, cutaneous and extranodal subtypes. Diagnosis is challenging because reactive T-cell infiltrates can mimic lymphoma. Treatment varies by subtype and may include chemotherapy, targeted agents, radiotherapy, transplant or clinical trials.
Expert haematopathology review is essential. Immunohistochemistry, T-cell receptor clonality and molecular studies support the diagnosis. Staging includes imaging and subtype-specific assessment.
Treatment depends on subtype and stage. Options include CHOP-like chemotherapy, CD30-directed therapy, other targeted agents, radiotherapy and transplant. Clinical trials are important in relapsed disease.
Management is individualized and discussed with benefits, limitations, and follow-up.
There is no proven prevention. Prompt biopsy of persistent or atypical skin or nodal lesions is the main practical step.
Red flags — seek urgent care
Some subtypes are potentially curable with intensive therapy, while others are more resistant. Prognosis depends on subtype, stage and response.
T-cell lymphomas can be difficult to distinguish from reactive conditions. Expert review and molecular studies reduce misdiagnosis and guide treatment.
Cutaneous T-cell lymphoma arises primarily in the skin and may cause patches, plaques or tumours. Treatment is often skin-directed but can include systemic therapy in advanced disease.
Autologous or allogeneic transplant may be considered in selected fit patients with high-risk or relapsed disease.
CD30-directed therapy, histone deacetylase inhibitors, and other agents are used in selected subtypes. Availability and eligibility vary.
Clinical trials are important in T-cell lymphoma because standard options are limited in relapsed disease. Discuss eligibility with the treating team.
Immunosuppression from the disease and treatment increases infection risk. Fever needs urgent review.
Regular clinical review, imaging when indicated, skin assessment for cutaneous subtypes and survivorship care.
Diagnosis, staging and treatment planning for Hodgkin and non-Hodgkin lymphomas.
Donor stem cell transplant for selected high-risk blood cancers and marrow failure.
Eligibility assessment, referral coordination and follow-up for CAR-T cell therapy.
Non-Hodgkin lymphoma is a group of lymphoid cancers that includes indolent and aggressive subtypes.
Diffuse large B-cell lymphoma is the most common aggressive lymphoma, typically presenting as a rapidly growing mass.
Graft-versus-host disease is a complication of allogeneic transplant in which donor immune cells attack recipient tissues.
Content on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.
Reviewed by Dr. Jitendra Prasad Yadav • Last reviewed: 2026-11-10
Content is educational and aligns with standard medical references; individual evaluation may vary. External links provide context and do not imply endorsement.
Doctor — medically reviewed
Dr. Sachita Baniya
Consultant Haemato-Oncologist & Clinical Hematologist • MBBS, FCPS (Clinical Haematology) • NMC 20158
This condition guide was medically reviewed by Dr. Sachita Baniya.
On this site
Article information
Emergency
For sudden neurologic change, thunderclap headache, or seizure >5 min, seek emergency services now.